Biopsy is a medical test performed to examine and remote cancerous tissues from the body. Higher awareness about breast cancer’s adequate treatment, screening programs with regular checkups along with minimal caustic procedure is the energizing factors for developing the global market of breast biopsy devices.
Global Breast Biopsy Devices Market is expected to gain US$2,399 Mn by 2022 that expanding at CAGR of 10.6% during the forecast period of 2016-2022.
Browse Full Report of Breast Biopsy Devices Market – Size, Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2022 at http://www.credenceresearch.com/report/breast-biopsy-devices-market
The geographical distribution of the global breast biopsy devices market considered in this study encompasses regional markets such as North America, Europe, Asia Pacific, Middle East and North Africa and rest of the world.
In regional segmentation North America accounted the largest market share of breast biopsy devices followed with Europe and Asia-Pacific respectively. Increasing governmental support in order to improve the healthcare segment of the society with advanced medication technologies especially in developed economies like the U.S. and Canada will grow the market of breast biopsy devices.
According to recent report approximately 2.8 million women are surviving with breast cancer in the U.S. and about 77% women were diagnosed with breast cancer at the age of 50. The Europe is accounted the second largest market share owing to large target population comprising 15% diagnosed annually. The breast biopsy devices market is mainly dominated by Asia-Pacific region during the forecast period and expected to witness the highest growth rate at CAGR of 12.6%.
The various breast biopsy types analyzed in this report are fine needle aspiration biopsy (FNAB), core needle biopsy (CNB), vacuum-assisted breast biopsy (VABB), and incision and excision biopsy; VABB devices accounted for almost 90% of the revenue in the breast biopsy market, while CT- guided biopsy segment is anticipated to grow at the highest CAGR of 6.3 % during the forecast period.
Based on the products types this market is segmented into needle based biopsy guns, biopsy guidance systems, biopsy forceps, biopsy needles and other equipment (Curettes, Punches, and Markers). The guidance systems market for breast biopsy devices market is categorized as stereotactic X-ray guided biopsy, ultrasound guided biopsy, MRI guided biopsy and without imaging guidance biopsy. On the other hand, MRI guided breast biopsy is being increasingly adopted in developed markets of North America and Western Europe, where the overall awareness about health and safety is higher.
The global market leaders of breast biopsy device market are Becton, Dickinson and company (U.S.), bard, Inc. (U.S.) and hologic Inc. (U.S.); while, hologic is the leader of the breast biopsy devices market share of over 40%, mammotome become the second leading competitor following with the bard Inc. (U.S.).
Growing government and global health organization initiatives to spread awareness about breast cancer and treated with newer developed technique boosting the global market of biopsy devices .As per global report one in eight women is at risk of developing breast cancer in between the age of 40yr-70yrs; the factors contributing to rise in breast cancer is over consumption of alcoholic drinks, lesser physical activities, improper diet and irregular routine at work place.